Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells
- 1 July 2015
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 209, 327-336
Abstract
No abstract availableKeywords
Funding Information
- Korea government (2012M2A2A7035589, 2014R1A5A2009242)
- National R&D Program for Cancer Control, Ministry of Health & Welfare, Korea (0720550–2)
This publication has 36 references indexed in Scilit:
- The quest to overcome resistance to EGFR-targeted therapies in cancerNature Medicine, 2013
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Phage display selection of peptides that home to atherosclerotic plaques: IL‐4 receptor as a candidate target in atherosclerosisJournal of Cellular and Molecular Medicine, 2008
- Interleukin-4 Cytotoxin Therapy Synergizes with Gemcitabine in a Mouse Model of Pancreatic Ductal AdenocarcinomaCancer Research, 2007
- EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2005
- Phage display-derived peptides as therapeutic alternatives to antibodiesDrug Discovery Today, 2004
- Overexpressed Cell Surface Interleukin-4 Receptor Molecules Can Be Successfully Targeted for Antitumor Cytotoxin TherapyCritical Reviews in Immunology, 2001
- Toxicologic Pathology of Cytokines, Cytokine Receptors, and Other Recombinant Human ProteinsToxicologic Pathology, 1999